ArticleJournal of neurology2025
Parkinson's disease-associated camptocormia: biopsy-confirmed focal myositis and treatment options.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe etiology of the disabling symptom camptocormia/dropped head in Parkinson's disease (PD) is still debated. Many PD patients develop involuntary flexion of the spine in an upright position that does not respond to dopaminergic treatment.
objectivesTo study the histopathology of paraspinal muscles in PD-associated camptocormia with potential consequences for therapy.
methodsWe report a cohort of 66 patients with PD (mean age 68.4 ± 8.1 years) and associated camptocormia according to consensus criteria. Paravertebral muscle biopsy was performed in all patients with consecutive histopathological analysis.
resultsForty-two patients (64%) showed inflammatory myositis in the paravertebral muscles with features of T-cell dominant myositis with additional necrosis, in addition to moderate myopathic changes. Thirty-four of these 42 patients with myositis received immunosuppression according to general clinical guidelines for myositis (i.e., prednisolone, often followed by azathioprine) in addition to PD medication. Twenty-three/34 patients (68%) on prednisolone showed a partial or complete improvement of the muscle weakness. This effect persisted after switching from prednisolone to the long-term immunosuppressant. Three/34 patients were lost to follow-up, and 8/34 did not improve.
conclusionsIn this cohort of PD patients with camptocormia, muscle biopsy demonstrated local myositis in addition to myopathic changes in 64% of the cases. About two-thirds of these patients benefited from prednisolone therapy, as a symptomatic therapeutic option for muscle weakness. We recommend a histological work-up of the clinical diagnosis PD-associated camptocormia given that effective therapeutic options are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.